pharma · Diabetes · Congenital Bleeding Disorder
Novo Nordisk A/S
Novo Nordisk A/S clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Novo Alle, Bagsværd, 2880, DK
- Founded
- 1923
- Employees
- 63,033
- Programs
- 40
- Drugs
- 46
- Patents
- 0
Novo Nordisk A/S projects
6 ClinicalTrials.gov programs sponsored by Novo Nordisk A/S.
Novo Nordisk A/S has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
KCT02/2023-SATELLITE
Novo Nordisk A/S
Arterial hypertension
1 trial -
KCT10/2022-LEASH
Novo Nordisk A/S
Hyperlipidaemia
1 trial -
KCT23/2022-ZOOM-IN
Novo Nordisk A/S
Knee osteoarthritis
1 trial -
biphasic insulin aspart 30
Novo Nordisk A/S
Diabetes
2 trials -
insulin detemir
Novo Nordisk A/S
Diabetes
2 trials -
turoctocog alfa
Novo Nordisk A/S
Congenital Bleeding Disorder
2 trials
Frequently asked questions
How many clinical projects does Novo Nordisk A/S have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.